Abstract
We have carried out an in vitro study of the growth inhibitory capacity of the neurokinin-1 receptor antagonist L-733,060 at concentrations ranging from 5μM to 40μM against the human pancreas adenocarcinoma CAPAN-1 and PA-TU 8902 cell lines. We also studied the mitogenic action of substance P on both cancer cell lines. A Coulter counter was used to determine viable cell numbers, followed by application of the MTS colorimetric method to evaluate cell viability in these cytotoxicity assays. Nanomolar concentrations of substance P increased the growth of both cell lines and micromolar concentrations of L-733,060 inhibited the growth of the CAPAN-1 and PA-TU 8902 cell lines studied in a dose-dependent manner. The IC50 values were 20.02μM for CAPAN-1 and 18.11μM for PA-TU 8902. In order to demonstrate the presence of neurokinin- 1 receptors in these cancer cell lines, an immunoblot analysis was used. Four bands of 34, 46, 58 and 75 kDa were observed in both cell lines. These new findings suggest that the neurokinin-1 receptor is a new target and that the neurokinin-1 receptor antagonist L-733,060 could be a promising therapeutic drug for the treatment of human pancreas adenocarcinoma.
Keywords: Pancreas adenocarcinoma, CAPAN-1, PA-TU 8902, cell proliferation, NK-1 receptor antagonists, tachykinins
Letters in Drug Design & Discovery
Title: The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Volume: 3 Issue: 5
Author(s): Miguel Munoz, Marisa Rosso and Rafael Covenas
Affiliation:
Keywords: Pancreas adenocarcinoma, CAPAN-1, PA-TU 8902, cell proliferation, NK-1 receptor antagonists, tachykinins
Abstract: We have carried out an in vitro study of the growth inhibitory capacity of the neurokinin-1 receptor antagonist L-733,060 at concentrations ranging from 5μM to 40μM against the human pancreas adenocarcinoma CAPAN-1 and PA-TU 8902 cell lines. We also studied the mitogenic action of substance P on both cancer cell lines. A Coulter counter was used to determine viable cell numbers, followed by application of the MTS colorimetric method to evaluate cell viability in these cytotoxicity assays. Nanomolar concentrations of substance P increased the growth of both cell lines and micromolar concentrations of L-733,060 inhibited the growth of the CAPAN-1 and PA-TU 8902 cell lines studied in a dose-dependent manner. The IC50 values were 20.02μM for CAPAN-1 and 18.11μM for PA-TU 8902. In order to demonstrate the presence of neurokinin- 1 receptors in these cancer cell lines, an immunoblot analysis was used. Four bands of 34, 46, 58 and 75 kDa were observed in both cell lines. These new findings suggest that the neurokinin-1 receptor is a new target and that the neurokinin-1 receptor antagonist L-733,060 could be a promising therapeutic drug for the treatment of human pancreas adenocarcinoma.
Export Options
About this article
Cite this article as:
Munoz Miguel, Rosso Marisa and Covenas Rafael, The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines, Letters in Drug Design & Discovery 2006; 3 (5) . https://dx.doi.org/10.2174/157018006777574168
DOI https://dx.doi.org/10.2174/157018006777574168 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Optimal Saturated Neuropilin-1 Expression in Normal Tissue Maximizes Tumor Exposure to Anti-Neuropilin-1 Monoclonal Antibody
Anti-Cancer Agents in Medicinal Chemistry Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Production of β -cyclodextrin from pH and Thermo Stable Cyclodextrin Glycosyl Transferase, Obtained from Arthrobacter mysorens and Its Evaluation as a Drug Carrier for Irbesartan
Current Drug Delivery Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Discovery of Biomarkers in Hepatocellular Carcinoma Metastasis Using Bioinformatic Analysis
Current Bioinformatics Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry Transcriptomics of Antipsychotic Drug Function: What have we Learned from Rodent Studies?
Current Psychopharmacology Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Current Signal Transduction Therapy Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation
Current Medicinal Chemistry Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Applications of Lentiviral Vectors for shRNA Delivery and Transgenesis
Current Gene Therapy Analytical Approaches for Assaying Metallodrugs in Biological Samples: Recent Methodological Developments and Future Trends
Current Drug Metabolism Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry Meet Our Editorial Board Member
Current Signal Transduction Therapy